Literature DB >> 11591565

Plasma markers of endothelial dysfunction in pulmonary hypertension.

G Cella1, F Bellotto, F Tona, A Sbarai, G Mazzaro, G Motta, J Fareed.   

Abstract

STUDY
OBJECTIVES: To evaluate and to correlate endothelial cell dysfunction, using recently available plasma markers, with the magnitude of pulmonary artery pressure in patients with severe pulmonary hypertension (PH).
DESIGN: Selected plasma markers of endothelial cell dysfunction were studied: nitric oxide (NO), thrombomodulin, tissue factor pathway inhibitor, and soluble endothelium, leukocyte, and platelet selectins (sE-, sL-, sP-selectins, respectively).
SETTING: Padova University Hospital and Department of Pathology and Pharmacology, Loyola University of Chicago, Chicago, IL. PATIENTS: Fifteen patients had severe PH (four men and 11 women; mean age, 49.7 +/- 2.9 years: seven patients had primary pulmonary hypertension [PPH] and eight patients had secondary pulmonary hypertension [SPH]), and 20 patients were healthy control subjects. MEASUREMENT AND
RESULTS: In patients with PH, sP- and sE-selectins were elevated, whereas sL-selectin was lower in comparison with the selectin levels in control subjects. However, the differences between patients with PH and control subjects were significant only for sL-selectin (p < 0.0001) and sE-selectin (p < 0.03). The NO level was significantly lower in patients with PH compared with the NO level in control subjects (p < 0.01). No difference in tissue factor pathway inhibitor level was noted between control subjects and patients with PH. Only a weak correlation was found between thrombomodulin plasma levels and magnitude of systolic pulmonary artery pressure (r = -0.528, p < 0.05).
CONCLUSIONS: Our data are in keeping with the evidence for significant endothelial cell dysfunction in patients with PH and the need for chronic anticoagulation believed to increase survival in these patients. In addition, these data seem to suggest a need for newer agents that are able to increase the antithrombotic endothelial function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591565     DOI: 10.1378/chest.120.4.1226

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity.

Authors:  Debbie Friedman; Jacqueline Szmuszkovicz; Miklos Rabai; Jon A Detterich; Jondavid Menteer; John C Wood
Journal:  J Heart Lung Transplant       Date:  2012-03-21       Impact factor: 10.247

2.  Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension.

Authors:  Jennifer E Pogoriler; Stuart Rich; Stephen L Archer; Aliya N Husain
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

3.  Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease.

Authors:  David M Smadja; Pascale Gaussem; Laetitia Mauge; Romaric Lacroix; Sophie Gandrille; Véronique Remones; Séverine Peyrard; Florence Sabatier; Damien Bonnet; Marilyne Lévy
Journal:  Pediatr Cardiol       Date:  2010-02-27       Impact factor: 1.655

4.  Increased levels of circulating adhesion molecules in neonates with congenital diaphragmatic hernia complicated by persistent pulmonary hypertension.

Authors:  Hiroyuki Kobayashi; Atsuyuki Yamataka; Tadaharu Okazaki; Geoffrey J Lane; Prem Puri; Takeshi Miyano
Journal:  Pediatr Surg Int       Date:  2003-12-13       Impact factor: 1.827

5.  Selectins and platelet-derived growth factor (PDGF) in schistosomiasis-associated pulmonary hypertension.

Authors:  Monica Lapa; Milena M P Acencio; Alberto Q Farias; Lisete R Teixeira; Caio J C Fernandes; Carlos P Jardim; Mario Terra-Filho
Journal:  Lung       Date:  2014-09-14       Impact factor: 2.584

6.  Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Akihiro Hirashiki; Shiro Adachi; Yoshihisa Nakano; Yoshihiro Kamimura; Shigetake Shimokata; Kyosuke Takeshita; Toyoaki Murohara; Takahisa Kondo
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

7.  Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.

Authors:  Julie A Bastarache; Ling Wang; Zhengming Wang; Kurt H Albertine; Michael A Matthay; Lorraine B Ware
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-29       Impact factor: 5.464

Review 8.  Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension.

Authors:  Xi-Qian Xing; Yan-Li Li; Yu-Xuan Zhang; Yi Xiao; Zhi-Dong Li; Li-Qiong Liu; Yu-Shan Zhou; Hong-Yan Zhang; Yan-Hong Liu; Li-Hui Zhang; Min Zhuang; Yan-Ping Chen; Sheng-Rong Ouyang; Xu-Wei Wu; Jiao Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 9.  Pulmonary hypertension: work in progress.

Authors:  Paul D Boyce; Aaron B Waxman
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

Review 10.  The Impact of Sex Chromosomes in the Sexual Dimorphism of Pulmonary Arterial Hypertension.

Authors:  Dan N Predescu; Babak Mokhlesi; Sanda A Predescu
Journal:  Am J Pathol       Date:  2022-02-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.